Morgan Woods Email & Phone Number

New York, Ny, Us

• Plan and perform chronic and sub-chronic Toxilogical GLP dietary and various dosing route studies in rodents• Perform medical device implantation studies for toxilogical evaluation in rabbits• Writing GLP protocols• Necropsy/Prosection

• Performed acute and chronic in vivo pharmacology studies at a CRO for internal partners and external clients.• Oral lipid tolerance test studies in mice for evaluation of novel compounds for NASH.• Oncology studies in mice (immune compromised and not), with cancer cell inoculations, tumor measurements• Ulcerative-colitis model studies in mice• Experimental Autoimmune Encephalomyelitis model in mice• IVIS (In Vivo Imaging System)

• Extensive experience running acute, intensive compound in vivo screens in various strains of mice and rats intended for the treatment of Type 2 diabetes. Extensive experience in new model development to further explore Type 2 diabetes with a focus on chronic rodent models• In vivo drug activity/efficacy screening for Type 2 diabetes and obesity targets• Glucose tolerance assays in mice and rats• Dosing and rodent surgeries• Feed intake studies in rodents• Data evaluation and reporting• New model development and writing research protocolsPerformed critical proof-of-concept/proof-of-biology pharmacodynamics experiments in the canine insulinemic pancreatic tracer-based clamp (hyperglycemic and euglycemic) model studies with accompanying PK/PD assays to screen for novel insulin candidates evaluated for prandial or basal insulin action. These studies were to help drive investigational compounds from the preclinical space into the “first in human” (FIH) clinical setting. • Canine (Beagles) handling• Injection and infusion• Blood collection in canines with implanted vascular portsManaged very large data sets generated from studies performed at external (CRO) non-human primate (NHP) laboratories, testing new chemical entities, peptides and biologics intended for the treatment of obesity, metabolic syndrome, Type 1 and Type 2 diabetes. Responsible for managing all colony management data generated for the monitoring of the overall health of these NHP colonies. • Received data, QC the data and upload the data into a central database (ELN/Bioassay) to be available for viewing and use in Spotfire• Collaborated with NHP team, principal scientists, IT team at Merck and the external partner in the planning and overseeing of the NHP studies

Tested novel compounds in various strains of mice and rats intended for the treatment of Type 2 diabetes and compounds intended for the treatment of obesity. The glucose tolerance assay was the in vivo model most often employed for screening and evaluation of potential glucose excursion modulating compounds. Three types of insulin/glucose clamps were often used as in vivo exploratory methods for various diabetes targets. • In vivo drug activity/efficacy screening for Type 2 diabetes and obesity targets• Glucose tolerance assays in mice and rats• Feed intake studies• Hyperglycemic, Euglycemic and Hyperinsulinemic-Euglycemic clamps in rats and mice• Dosing and rodent surgeries• Data evaluation and reporting• Plate assays, ELISA, for a multitude of metabolic analytes involved in glucose and energy metabolism• New model development and writing research protocols

• Tested novel compounds intended for the treatment of urinary incontinence in rat models of Neurogenic and Myogenic urinary bladder instability• Assessed the in vivo hemodynamic effects of compounds in rats with radio telemetry• In vivo drug activity/efficacy screening• Telemetry• Dosing, survival surgeries in rats, vessel cannulations, chronic transmitter implantation• Data evaluation and reporting• New model development and writing research protocols

Using molecular biology to clone genes of interest from cDNA libraries for use in high throughput screening and in the construction of expression vectors for transgenic expression in mice. Micro-injecting fertilized mouse embryos with linear DNA and re-implanting embryos into pseudo-pregnant host. Using RNAi (siRNA and shRNA) to look at the effects of selective gene silencing both in vitro and in vivo. Using Western blot analysis and immunohistochemical techniques as tools for assessing protein expression. Culturing multiple mammalian cell lines including mouse embryonic stem cells. Generating surgically modified rats for use in pain models (inflammatory, neuropathic, and incisional) • Molecular Biology o PCRo Cloning from cDNA librarieso BAC cloningo Nucleic acid extraction/purificationo Gel electrophoresiso Western blot analysiso Immunohistochemistryo Design of and use of RNAi (siRNA, shRNA)o Gene Targeting in miceo Cell culture, cell transfections, including embryonic stem cellso Pronuclear injection of fertilized mouse embryoso Histologyo Plate assays, ELISAo Microscopy• Rodent survival surgeries• Data evaluation and reporting 1996–2002 Research Scientist IWyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426 Tested novel compounds intended for the treatment of urinary incontinence in rat models of neurogenic, myogenic and isovolumetric urinary bladder instability. Assessed the in vivo hemodynamic effects of compounds in rats. Developed a method and performed experiments for in vivo screening of novel compounds to be used in the treatment of pre-term labor. • In vivo drug activity/efficacy screening• Dosing, survival surgeries in rats, vessel cannulations• Data evaluation and reporting

Tested novel compounds intended for the treatment of urinary incontinence in rat models of neurogenic, myogenic and isovolumetric urinary bladder instability. Assessed the in vivo hemodynamic effects of compounds in rats. Developed a method and performed experiments for in vivo screening of novel compounds to be used in the treatment of pre-term labor. • In vivo drug activity/efficacy screening• Dosing, survival surgeries in rats, vessel cannulations• Data evaluation and reporting